As global markets show signs of optimism, with the Hang Seng Index up 1.99% and technology stocks leading gains, Hong Kong’s tech sector is drawing significant investor attention. In this dynamic environment, identifying high-growth tech stocks requires a keen eye on companies that are not only innovating but also demonstrating strong fundamentals and market adaptability.
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Wasion Holdings | 22.71% | 25.80% | ★★★★★☆ |
| Be Friends Holding | 33.82% | 32.27% | ★★★★★★ |
| MedSci Healthcare Holdings | 45.88% | 45.90% | ★★★★★☆ |
| Inspur Digital Enterprise Technology | 21.83% | 38.02% | ★★★★★☆ |
| iDreamSky Technology Holdings | 29.81% | 104.11% | ★★★★★★ |
| Cowell e Holdings | 30.96% | 35.72% | ★★★★★★ |
| RemeGen | 26.30% | 52.19% | ★★★★★☆ |
| Innovent Biologics | 21.21% | 50.78% | ★★★★★☆ |
| Biocytogen Pharmaceuticals (Beijing) | 21.35% | 100.10% | ★★★★★☆ |
| Beijing Airdoc Technology | 31.64% | 83.90% | ★★★★★☆ |
Click here to see the full list of 47 stocks from our SEHK High Growth Tech and AI Stocks screener.
Let’s explore several standout options from the results in the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of antibody-based drugs, operating in China, the United States, and internationally, with a market cap of HK$2.52 billion.
Operations: Biocytogen Pharmaceuticals generates revenue primarily from animal model sales (CN¥293.68 million), pre-clinical pharmacology and efficacy evaluation (CN¥193.40 million), antibody development (CN¥175.87 million), and gene editing services (CN¥74.33 million).
Biocytogen Pharmaceuticals (Beijing) has demonstrated impressive growth, with revenue increasing by 34.3% over the past year and forecasted to grow at 21.3% annually, outpacing the Hong Kong market’s 7.4%. The company’s substantial R&D investments have resulted in a robust pipeline, including a recent agreement with IDEAYA Biosciences for a potential $406.5 million in milestone payments and royalties from their B7H3/PTK7 BsADC program. Additionally, Biocytogen’s antibody licensing business and innovative animal models continue to drive revenue, contributing significantly to its promising financial outlook despite current unprofitability.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Wasion Holdings Limited is an investment holding company that focuses on the research, development, production, and sale of energy metering and energy efficiency management solutions for the energy supply industries across various regions including China, Africa, the United States, Europe, and Asia; it has a market cap of approximately HK$6.51 billion.
Operations: Wasion Holdings Limited generates revenue primarily through three segments: Advanced Distribution Operations (CN¥2.48 billion), Power Advanced Metering Infrastructure (CN¥2.67 billion), and Communication and Fluid Advanced Metering Infrastructure (CN¥2.21 billion). The company is involved in the research, development, production, and sale of energy metering and energy efficiency management solutions for various regions including China, Africa, the United States, Europe, and Asia.
Wasion Holdings has shown remarkable growth, with earnings surging by 61% over the past year, significantly outperforming the Electronic industry’s 7.2% decline. The company’s revenue is expected to grow at an impressive 22.7% annually, outpacing the Hong Kong market’s 7.4%. Notably, Wasion’s R&D expenses have contributed to its innovative edge; in the last fiscal year alone, they allocated approximately RMB 247 million towards research and development efforts. Recent contracts from Hungary (EUR 31.62 million), Singapore (USD 9.42 million), and Malaysia (USD 5.74 million) underscore their expanding international footprint and client trust in their smart meter solutions.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Alphamab Oncology, a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and commercialization of oncology biologics with a market cap of approximately HK$2.36 billion.
Operations: Alphamab Oncology generates revenue primarily from the sale of pharmaceuticals, totaling CN¥255.87 million. The company specializes in developing and commercializing biologics for cancer treatment.
Alphamab Oncology reported a 27.2% increase in sales for the half year ending June 30, 2024, reaching CNY 173.56 million. Despite a net loss of CNY 44.9 million, the company’s R&D expenses underscore its commitment to innovation; their JSKN003 anti-HER2 bispecific ADC has shown promising results in clinical studies across Australia and China. With revenue projected to grow at an impressive annual rate of 39.4%, Alphamab’s focus on advanced oncology treatments positions it well within the high-growth tech landscape in Hong Kong.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Discover if Biocytogen Pharmaceuticals (Beijing) might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
